GCG and diabetic kidney disease: Future reviews should be conducted with trials studying the use of GLP1-RAs in a focused population of patients with DKD, like the aforementioned FLOW trial, to understand their direct reduction of UACR, adverse renal outcomes, and ESRD incidence.